Navigation Links
Bioenergy D-Ribose Achieves Highest Safety Standard
Date:11/20/2008

MINNEAPOLIS, Nov. 20 /PRNewswire/ -- Integrative life science company Bioenergy, Inc. has achieved GRAS status (generally recognized as safe) from the U.S. Food and Drug Administration (FDA) for its core energy nutrient D-ribose, a naturally occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP) -- an essential energy compound.

"The FDA's written response that it has reviewed the submitted safety evidence and has no questions about the GRAS determination for D-ribose is the government's highest recognition of a food ingredient for safety and purity," said Raj Khankari, Ph.D., CEO of Bioenergy, Inc. The company has held "self-affirmed" GRAS status for years. "Today, we are gratified that the FDA has officially validated our assessment."

"The FDA's 'no questions letter' signals to the major food and beverage manufacturers that we have invested all the resources possible to guarantee the quality and safety of our D-ribose products for the benefit of customers and consumers."

Bioenergy has amassed a large body of scientific literature regarding uses of ribose for people across all age and health categories. The company has more than 40,000 customers for its proprietary Corvalen products alone, and millions worldwide use Bioenergy ribose in other products. It is commonly found in functional foods like energy bars (Detour, FastFuel, Marathon) and beverages (SoBe Adrenaline Rush, Vitamin Water, Snapple Antioxidant Water). Currently, Bioenergy D-ribose is included as an ingredient in approximately 100 products.

In larger quantities as a Medical Food, D-Ribose also has been shown to assist patients with compromised heart function and is also widely used by patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS).

Bioenergy, Inc. (http://www.bioenergy.com) is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose for health and wellness. In addition to a pharmaceutical subsidiary, Bioenergy has two other companies. Bioenergy Life Science, Inc. manufactures and sells D-ribose as an ingredient to nutraceutical firms for beverages and foods; as a medical food through doctors and clinics; and as a dietary supplement for energy recovery (reduces fatigue, muscle pain, soreness and stiffness following exercise). Viacell, LLC is developing technology related to the enhancement of blood components.


'/>"/>
SOURCE Bioenergy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Media Advisory - Atlantica BioEnergy Task Force Leaders Roundtable
2. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
3. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
4. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
5. Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock
6. Raj Khankari Named Bioenergy, Inc., CEO
7. Atlantica BioEnergy Task Force Unveiled
8. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
9. BioEnergy International Facility Opens in Bay State
10. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
11. D-Ribose Helps Energy-Starved Hearts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):